ES2028492A6 - Procedimiento de obtencion de hidrosoles de agentes farmacologicamente activos. - Google Patents

Procedimiento de obtencion de hidrosoles de agentes farmacologicamente activos.

Info

Publication number
ES2028492A6
ES2028492A6 ES8703635A ES8703635A ES2028492A6 ES 2028492 A6 ES2028492 A6 ES 2028492A6 ES 8703635 A ES8703635 A ES 8703635A ES 8703635 A ES8703635 A ES 8703635A ES 2028492 A6 ES2028492 A6 ES 2028492A6
Authority
ES
Spain
Prior art keywords
hydrosols
procedure
obtaining
active agents
pharmacologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8703635A
Other languages
English (en)
Inventor
Martin List
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6316557&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2028492(A6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Publication of ES2028492A6 publication Critical patent/ES2028492A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROCEDIMIENTO DE OBTENCION DE HIDROSOLES DE AGENTES FARMACOLOGICAMENTE ACTIVOS, CARACTERIZADO PORQUE UNA SOLUCION DE UNA SUSTANCIA ACTIVA DE DIFICIL SOLUBILIDAD EN AGUA, EN UN DISOLVENTE ORGANICO MISCIBLE CON AGUA, SE MEZCLA CON AGUA EN UNA RELACION EN PESO ENTRE LA SUSTANCIA ACTIVA Y EL AGUA COMPRENDIDA ENTRE 1:800 Y 1:300, BAJO CONDICIONES TALES QUE, EN EL DISOLVENTE ORGANICO ESTE PRESENTE UN COLOIDE INSOLUBLE EN AGUA, Y/O EN EL AGUA ESTE PRESENTE UN COLOIDE HIDROSOLUBLE, GRACIAS A LO CUAL SE CONSIGUE ESTABILIZAR EL HIDROSOL DE SUSTANCIA ACTIVA QUE SE HA DE FORMAR, Y PRODUCIR UN HIDROSOL DE PARTICULAS SOLIDAS DE SUSTANCIA ACTIVA, HIDROSOL QUE SE SECA, SI SE DESEA, A UNA FORMA SUSCEPTIBLE DE SER RESUSPENDIDA EN AGUA. EL HIDROSOL CONTIENE PARTICULAS SOLIDAS DE SUSTANCIA ACTIVA, POR EJEMPLO DE DIHIDROPIRIDINAS O DE CICLOSPORINAS.
ES8703635A 1986-12-19 1987-12-18 Procedimiento de obtencion de hidrosoles de agentes farmacologicamente activos. Expired - Lifetime ES2028492A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3643392 1986-12-19

Publications (1)

Publication Number Publication Date
ES2028492A6 true ES2028492A6 (es) 1992-07-01

Family

ID=6316557

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8703635A Expired - Lifetime ES2028492A6 (es) 1986-12-19 1987-12-18 Procedimiento de obtencion de hidrosoles de agentes farmacologicamente activos.

Country Status (25)

Country Link
US (1) US5389382A (es)
JP (1) JP2617958B2 (es)
KR (1) KR960005136B1 (es)
AT (1) AT397914B (es)
BE (1) BE1000848A3 (es)
CA (1) CA1308656C (es)
CH (1) CH679451A5 (es)
DD (1) DD281344A5 (es)
DE (1) DE3742473C2 (es)
DK (2) DK173319B1 (es)
ES (1) ES2028492A6 (es)
FR (1) FR2608427B1 (es)
GB (1) GB2200048B (es)
GR (1) GR871938B (es)
HU (1) HU205861B (es)
IE (1) IE61179B1 (es)
IL (1) IL84855A (es)
IT (1) IT1230118B (es)
LU (1) LU87079A1 (es)
MY (1) MY102037A (es)
NL (1) NL194638C (es)
NZ (1) NZ222964A (es)
PT (1) PT86399B (es)
SE (1) SE503020C2 (es)
ZA (1) ZA879533B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
US5399363A (en) * 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE4140172C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Ibuprofen enthaltendes Arzneimittel
DE4140194C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Ein Dihydropyridinderivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140184C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
CA2125282C (en) * 1991-12-05 1999-08-31 Jens-Christian Wunderlich Pharmaceutically applicable nanosol and process for preparing the same
DE4140195C2 (de) * 1991-12-05 1994-10-27 Alfatec Pharma Gmbh Pharmazeutisch applizierbares Nanosol und Verfahren zu seiner Herstellung
DE4140185C2 (de) * 1991-12-05 1996-02-01 Alfatec Pharma Gmbh Ein 2-Arylpropionsäurederivat in Nanosolform enthaltendes Arzneimittel und seine Herstellung
DE4140183C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Retardform für ein Flurbiprofen enthaltendes Arzneimittel
DE4140191C2 (de) * 1991-12-05 1998-02-19 Alfatec Pharma Gmbh Retardform für ein Indometacin oder Acemetacin enthaltendes Arzneimittel und seine Herstellung
DE4140179C2 (de) * 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
KR0146671B1 (ko) * 1994-02-25 1998-08-17 김충환 사이클로스포린-함유 분말 조성물
DE4440337A1 (de) * 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5834017A (en) * 1995-08-25 1998-11-10 Sangstat Medical Corporation Oral cyclopsporin formulations
US5827822A (en) * 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5766629A (en) * 1995-08-25 1998-06-16 Sangstat Medical Corporation Oral cyclosporin formulations
US5962019A (en) * 1995-08-25 1999-10-05 Sangstat Medical Corporation Oral cyclosporin formulations
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP1369111A1 (en) * 1996-10-03 2003-12-10 Hermes Biosciences, Inc. Hydrophilic microparticles and methods to prepare same
US6249717B1 (en) * 1996-11-08 2001-06-19 Sangstat Medical Corporation Liquid medication dispenser apparatus
US6008191A (en) * 1997-09-08 1999-12-28 Panacea Biotec Limited Pharmaceutical compositions containing cyclosporin
US6187747B1 (en) 1997-09-08 2001-02-13 Panacea Biotech Limited Pharmaceutical composition comprising cyclosporin
US6346511B1 (en) 1997-09-08 2002-02-12 Panacea Biotec Limited Pharmaceutical composition comprising cyclosporin
AU750245B2 (en) 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
US6447806B1 (en) 1999-02-25 2002-09-10 Novartis Ag Pharmaceutical compositions comprised of stabilized peptide particles
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6656504B1 (en) * 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
DE10040707A1 (de) * 2000-08-17 2002-03-14 Braun Melsungen Ag Kolloidale Pharmakomodulation injizierter Arzneimittel
EP2116228A1 (en) * 2001-10-19 2009-11-11 Isotechnika Inc. Novel cyclosporin analog microemulsion preconcentrates
WO2003033526A2 (en) 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
DE10205362A1 (de) * 2002-02-08 2003-08-21 Abbott Gmbh & Co Kg Verfahren zur Herstellung wasserdispergierbarer Trockenpulver von in Wasser schwer löslichen Verbindungen
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
DE10234784A1 (de) * 2002-07-30 2004-02-19 Günenthal GmbH Intravenös applizierbare, pharmazeutische Darreichungsform
US7838034B2 (en) 2002-07-30 2010-11-23 Grunenthal Gmbh Intravenous pharmaceutical form of administration
EP1592406A2 (en) * 2003-02-13 2005-11-09 Phares Pharmaceutical Research N.V. Lipophilic compositions
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
JP5080445B2 (ja) * 2005-04-13 2012-11-21 アボット ゲーエムベーハー ウント コー． カーゲー 超微粒子懸濁液及び超微粒子を穏やかに製造する方法並びにその使用
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
CA2669392C (en) 2006-11-17 2016-05-10 Abbott Gmbh & Co. Kg Nanocrystals for use in topical cosmetic formulations and method of production thereof
DE102007001473A1 (de) 2007-01-08 2008-07-10 Andreas Lemke Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
CA2683712A1 (en) * 2007-04-20 2009-01-15 Sun Pharmaceutical Industries Limited Pharmaceutical compositions
JP5149585B2 (ja) * 2007-10-02 2013-02-20 浜松ホトニクス株式会社 微粒子分散液製造方法
JP5161528B2 (ja) * 2007-10-02 2013-03-13 浜松ホトニクス株式会社 パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法
US20090087460A1 (en) * 2007-10-02 2009-04-02 Hamamatsu Photonics K.K. Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these
EP2257220B1 (en) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Multi-function, foot-activated controller for imaging system
HU230862B1 (hu) 2008-04-28 2018-10-29 DARHOLDING Vagyonkezelő Kft Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
DE102008037025C5 (de) 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
WO2011079232A1 (en) * 2009-12-23 2011-06-30 Psivida Us, Inc. Sustained release delivery devices
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2583672A1 (en) 2011-10-17 2013-04-24 PharmaSol GmbH Nanocrystals and amorphous nanoparticles and method for production of the same by a low energy process
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
EP3616688A1 (en) * 2018-08-27 2020-03-04 Centre National de la Recherche Scientifique - CNRS Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107288A (en) * 1870-09-13 Improvement in thread-spools
DE738604C (de) * 1935-07-09 1943-08-23 Rudolf Degkwitz Dr Verfahren zur Herstellung von Hydrosolen mit waehlbarer Gestalt und waehlbarer Groesse der kolloiden Teilchen
JPS5831210B2 (ja) * 1973-04-09 1983-07-05 武田薬品工業株式会社 アンテイナスイセイケンダクエキノセイゾウホウ
DE2362785A1 (de) * 1973-12-18 1975-06-26 Atmos Fritzsching & Co Gmbh Verfahren zum haltbarmachen von kristallsuspensionen
FR2257266B1 (es) * 1974-01-10 1977-07-01 Pasteur Institut
US4107288A (en) * 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
CA1098444A (en) * 1975-05-26 1981-03-31 Leo Geller Peptide preparations with prolonged action
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
US4361580A (en) * 1980-06-20 1982-11-30 The Upjohn Manufacturing Company Aluminum ibuprofen pharmaceutical suspensions
IT1209276B (it) * 1980-11-05 1989-07-16 Magis Farmaceutici Composizione farmaceutica per la somministrazione orale del metilestere dell'acido 13a-etil-2,3,5,6,12,13,13a,13b-ottaidro-12-idrossi1h-indolo-[3,2,1-de] pirido [3,2,1-ij] [1,5] naftiridina -12-carbossilico
PH20649A (en) * 1981-09-22 1987-03-16 Gist Brocades Nv Bismuth containing composition and method for the preparation thereof
GB8322364D0 (en) * 1983-08-19 1983-09-21 May & Baker Ltd Compositions of matter
CA1239349A (en) * 1983-10-10 1988-07-19 Eberhard F. Gottwald Pharmaceutical composition containing cimetidine
EP0138216B1 (en) * 1983-10-14 1993-01-07 Sumitomo Pharmaceuticals Company, Limited Sustained-release ifn preparation for parenteral administration
JPS60139688A (ja) * 1983-12-28 1985-07-24 Tokyo Tanabe Co Ltd 無定形ジヒドロピリジン粉末製剤
DE3347579A1 (de) * 1983-12-30 1985-07-11 Hoechst Ag, 6230 Frankfurt Zubereitungen schwer wasserloeslicher anthelminthika und verfahren zu ihrer herstellung
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
DE3515335C2 (de) * 1985-04-27 1995-01-26 Bayer Ag Arzneizubereitung enthaltend Dihydropyridine und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
HUT52941A (en) 1990-09-28
DD281344A5 (de) 1990-08-08
NL194638B (nl) 2002-06-03
KR880007061A (ko) 1988-08-26
FR2608427B1 (fr) 1991-02-08
SE8705043L (sv) 1988-06-20
FR2608427A1 (fr) 1988-06-24
GR871938B (en) 1988-04-05
AU606908B2 (en) 1991-02-21
BE1000848A3 (fr) 1989-04-18
IT1230118B (it) 1991-10-07
DE3742473A1 (de) 1988-07-28
PT86399B (pt) 1994-10-31
GB2200048A (en) 1988-07-27
JP2617958B2 (ja) 1997-06-11
IL84855A (en) 1992-03-29
PT86399A (pt) 1989-01-17
DE3742473C2 (de) 1998-11-19
IL84855A0 (en) 1988-06-30
IT8748729A0 (it) 1987-12-18
DK173345B1 (da) 2000-08-07
NL194638C (nl) 2002-10-04
MY102037A (en) 1992-02-29
DK200000266A (da) 2000-02-21
IE873425L (en) 1988-06-19
DK664187A (da) 1988-06-20
SE8705043D0 (sv) 1987-12-17
JPS63165312A (ja) 1988-07-08
HU205861B (en) 1992-07-28
ZA879533B (en) 1989-08-30
KR960005136B1 (ko) 1996-04-22
AT397914B (de) 1994-08-25
CH679451A5 (es) 1992-02-28
SE503020C2 (sv) 1996-03-11
NL8702998A (nl) 1988-07-18
IE61179B1 (en) 1994-10-05
NZ222964A (en) 1991-01-29
US5389382A (en) 1995-02-14
LU87079A1 (fr) 1988-07-14
DK664187D0 (da) 1987-12-17
ATA333087A (de) 1993-12-15
AU8282887A (en) 1988-06-23
GB2200048B (en) 1991-02-06
DK173319B1 (da) 2000-07-24
GB8729404D0 (en) 1988-02-03
CA1308656C (en) 1992-10-13

Similar Documents

Publication Publication Date Title
SE8705043D0 (sv) Hydrosols of pharmacologically active agents and their pharmaceutical compositions comprising them
DE68901043D1 (de) Waessriges pharmazeutisches praeparat.
DK0501985T3 (da) Uovertrukket farmaceutisk reaktionstablet
UA27043C2 (uk) Мікросферичhі частиhки для пареhтеральhої іh'єкції фармацевтичhо активhої речовиhи при її коhтрольоваhому виділеhhі в оргаhізмі після іh'єкції, спосіб їх одержаhhя та суспеhзія hа осhові даhих мікросфер
NL300057I2 (nl) Farmacologisch actieve 1,5-diaryl-3-gesubstitueerde-pyrazolen en werkwijze voor het synthetiseren e rvan.
MY100998A (en) Pharmaceutical formulations
IT1246188B (it) Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
EP0979225A4 (en) COMPOUNDS AND COMPOSITIONS FOR ADMINISTRATION OF ACTIVE AGENTS
EP0260418A3 (en) Active suspension system providing inhibition of vehicle body vertical oscillation, and method of operation thereof
EA200200119A1 (ru) β-КАРБОЛИНОВЫЕ ЛЕКАРСТВЕННЫЕ ПРОДУКТЫ
IT1238343B (it) Procedimento per la preparazione di vaccini capaci di generare non solo la risposta immune dei linfociti t helper,ma anche un'efficace risposta di linfociti t citotossici,e vaccini con queste caratteristiche
AR242561A1 (es) Procedimiento para la preparacion de clorhidrato de s-(-)-1-propil-2',6'-pipecoloxilidida opticamente sustancialmente puro y procedimiento
SE8800080D0 (sv) Lekemedelskomposition
NO172438C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive ((5(6)(1h-azol-1-ylmetyl)benzimidazol)karbamater
NO921603D0 (no) Fremgangsmaate til fremstilling av et aktivt findelt agregat for bruk til betong
ITMI911315A1 (it) Corpo di cuscino e procedimento per la formazione del medesimo
NO871190D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive substituerte anilider.
ZA909624B (en) Transdermal system for administering pharmacological compounds under ph-control
NO880922D0 (no) Fremgangsmaate for fremstilling av farmakologisk aktive benzodioksolderivater.
AR016869A1 (es) Metodo para preparar una suspension farmaceutica acuosa de nevirapina, dicha suspension farmaceutica y uso de nevirapina para preparar dicha suspensionfarmaceutica
IT8748573A0 (it) Impiego di magnesite per la modificazione e/o l'espansione di scorie metallurgiche,e relativo procedimento
ITRM950143A0 (it) Uso di 2-amminotetraline-6,7-sostituite per la preparazione di composizioni farmaceutiche atte al trattamento dello shock, e di composizioni farmaceutiche antipiretiche ed antinfiammatorie.
MX174642B (es) Formulaciones farmaceuticas
BR6500774U (pt) Piso ceramico assentado sobre areia fina sem o uso do lastro ou piso morto
IT8819959A0 (it) Derivati alcossibenzimidazolici farmacologicamente attivi eprocedimento di preparazione.

Legal Events

Date Code Title Description
PC1A Transfer granted
FD1A Patent lapsed

Effective date: 20071219